Less than two years after revealing a multimillion-dollar upgrade plan for its plant in Macclesfield, U.K., AstraZeneca is cutting back, slashing almost 100 jobs in what a local union called a “hammer blow” to U.K. manufacturing. More: AstraZeneca to cut
read moreAstraZeneca’s Farxiga just won European approval in Type 1 diabetes, but its prospects in the U.S. are less certain. The FDA’s rejection of Sanofi and Lexicon Pharmaceuticals’ would-be rival Zynquista may serve as an ill omen in Type 1 for
read moreTurns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger. The Federal Trade Commission is taking a closer look at the companies’ psoriasis drugs, both those on the market and those
read moreMerck CEO Kenneth Frazier is dealing with challenges ranging from lawmakers’ criticisms over high drug prices to pressure to find revenue-growth opportunities beyond the company’s immuno-oncology blockbuster Keytruda. But he remains unfazed, thanks to advice his father gave him when
read moreIn the third announcement about cell and gene manufacturing within the week, Belgium-based Masthercell Global says it will build out a commercial-scale facility in its home country. More: Masthercell adds to global gene and cell manufacturing frenzy with EU facility
read moreFacing a long list of opioid mismarketing lawsuits, Purdue has agreed to its first settlement, according to numerous anonymously sourced media reports. Oklahoma’s attorney general Mike Hunter is expected to announce the deal Tuesday afternoon. More: As Purdue settles first
read more© 1994 - 2026 B.M. Pharmaceuticals